Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 232

1.

Structural basis of a potent human monoclonal antibody against Zika virus targeting a quaternary epitope.

Long F, Doyle M, Fernandez E, Miller AS, Klose T, Sevvana M, Bryan A, Davidson E, Doranz BJ, Kuhn RJ, Diamond MS, Crowe JE Jr, Rossmann MG.

Proc Natl Acad Sci U S A. 2019 Jan 14. pii: 201815432. doi: 10.1073/pnas.1815432116. [Epub ahead of print]

PMID:
30642974
2.

Multistate design of influenza antibodies improves affinity and breadth against seasonal viruses.

Sevy AM, Wu NC, Gilchuk IM, Parrish EH, Burger S, Yousif D, Nagel MBM, Schey KL, Wilson IA, Crowe JE Jr, Meiler J.

Proc Natl Acad Sci U S A. 2019 Jan 14. pii: 201806004. doi: 10.1073/pnas.1806004116. [Epub ahead of print]

3.

Influenza Virus-Specific Human Antibody Repertoire Studies.

Crowe JE Jr.

J Immunol. 2019 Jan 15;202(2):368-373. doi: 10.4049/jimmunol.1801459. Review.

PMID:
30617118
4.

Current Understanding of Humoral Immunity to Enterovirus D68.

Vogt MR, Crowe JE Jr.

J Pediatric Infect Dis Soc. 2018 Dec 26;7(suppl_2):S49-S53. doi: 10.1093/jpids/piy124. Review.

PMID:
30590621
5.

Increased breadth of HIV-1 neutralization achieved by diverse antibody clones each with limited neutralization breadth.

Chukwuma VU, Kose N, Sather DN, Sapparapu G, Falk R, King H, Singh V, Lampley R, Malherbe DC, Ditto NT, Sullivan JT, Barnes T, Doranz BJ, Labranche CC, Montefiori DC, Kalams SA, Haigwood NL, Crowe JE Jr.

PLoS One. 2018 Dec 19;13(12):e0209437. doi: 10.1371/journal.pone.0209437. eCollection 2018.

6.

ANTIBODY-MEDIATED PROTECTIVE MECHANISMS INDUCED BY A TRIVALENT PARAINFLUENZA-VECTORED EBOLAVIRUS VACCINE.

Kimble JB, Malherbe DC, Meyer M, Gunn BM, Karim MM, Ilinykh PA, Iampietro M, Mohamed KS, Negi S, Gilchuk P, Huang K, Wolf YI, Braun W, Crowe JE Jr, Alter G, Bukreyev A.

J Virol. 2018 Dec 5. pii: JVI.01845-18. doi: 10.1128/JVI.01845-18. [Epub ahead of print]

PMID:
30518655
7.

Human mAbs to Staphylococcus aureus IsdA Provide Protection Through Both Heme-Blocking and Fc-Mediated Mechanisms.

Bennett MR, Bombardi RG, Kose N, Parrish EH, Nagel MB, Petit RA 3rd, Read TD, Schey KL, Thomsen IP, Skaar EP, Crowe JE Jr.

J Infect Dis. 2018 Nov 29. doi: 10.1093/infdis/jiy635. [Epub ahead of print]

PMID:
30496483
8.

Mechanism of Enhanced Immature Dengue Virus Attachment to Endosomal Membrane Induced by prM Antibody.

Wirawan M, Fibriansah G, Marzinek JK, Lim XX, Ng TS, Sim AYL, Zhang Q, Kostyuchenko VA, Shi J, Smith SA, Verma CS, Anand G, Crowe JE Jr, Bond PJ, Lok SM.

Structure. 2018 Oct 30. pii: S0969-2126(18)30370-8. doi: 10.1016/j.str.2018.10.009. [Epub ahead of print]

PMID:
30471923
9.

A protective human monoclonal antibody targeting the West Nile virus E protein preferentially recognizes mature virions.

Goo L, Debbink K, Kose N, Sapparapu G, Doyle MP, Wessel AW, Richner JM, Burgomaster KE, Larman BC, Dowd KA, Diamond MS, Crowe JE Jr, Pierson TC.

Nat Microbiol. 2019 Jan;4(1):71-77. doi: 10.1038/s41564-018-0283-7. Epub 2018 Nov 19.

PMID:
30455471
10.

Protective antibodies against Eastern equine encephalitis virus bind to epitopes in domains A and B of the E2 glycoprotein.

Kim AS, Austin SK, Gardner CL, Zuiani A, Reed DS, Trobaugh DW, Sun C, Basore K, Williamson LE, Crowe JE Jr, Slifka MK, Fremont DH, Klimstra WB, Diamond MS.

Nat Microbiol. 2019 Jan;4(1):187-197. doi: 10.1038/s41564-018-0286-4. Epub 2018 Nov 19.

PMID:
30455470
11.

Broadly Neutralizing Antibody Mediated Clearance of Human Hepatitis C Virus Infection.

Kinchen VJ, Zahid MN, Flyak AI, Soliman MG, Learn GH, Wang S, Davidson E, Doranz BJ, Ray SC, Cox AL, Crowe JE Jr, Bjorkman PJ, Shaw GM, Bailey JR.

Cell Host Microbe. 2018 Nov 14;24(5):717-730.e5. doi: 10.1016/j.chom.2018.10.012.

PMID:
30439341
12.

HCV Broadly Neutralizing Antibodies Use a CDRH3 Disulfide Motif to Recognize an E2 Glycoprotein Site that Can Be Targeted for Vaccine Design.

Flyak AI, Ruiz S, Colbert MD, Luong T, Crowe JE Jr, Bailey JR, Bjorkman PJ.

Cell Host Microbe. 2018 Nov 14;24(5):703-716.e3. doi: 10.1016/j.chom.2018.10.009.

PMID:
30439340
13.

In Vivo Delivery of Synthetic Human DNA-Encoded Monoclonal Antibodies Protect against Ebolavirus Infection in a Mouse Model.

Patel A, Park DH, Davis CW, Smith TRF, Leung A, Tierney K, Bryan A, Davidson E, Yu X, Racine T, Reed C, Gorman ME, Wise MC, Elliott STC, Esquivel R, Yan J, Chen J, Muthumani K, Doranz BJ, Saphire EO, Crowe JE, Broderick KE, Kobinger GP, He S, Qiu X, Kobasa D, Humeau L, Sardesai NY, Ahmed R, Weiner DB.

Cell Rep. 2018 Nov 13;25(7):1982-1993.e4. doi: 10.1016/j.celrep.2018.10.062.

14.

Potent Neutralizing Human Monoclonal Antibodies Preferentially Target Mature Dengue Virus Particles: Implication for Novel Strategy for Dengue Vaccine.

Tsai WY, Chen HL, Tsai JJ, Dejnirattisai W, Jumnainsong A, Mongkolsapaya J, Screaton G, Crowe JE Jr, Wang WK.

J Virol. 2018 Nov 12;92(23). pii: e00556-18. doi: 10.1128/JVI.00556-18. Print 2018 Dec 1.

PMID:
30185598
15.

Human Monoclonal Antibodies That Neutralize Pandemic GII.4 Noroviruses.

Alvarado G, Ettayebi K, Atmar RL, Bombardi RG, Kose N, Estes MK, Crowe JE Jr.

Gastroenterology. 2018 Dec;155(6):1898-1907. doi: 10.1053/j.gastro.2018.08.039. Epub 2018 Aug 28.

PMID:
30170116
16.

Asymmetric antiviral effects of ebolavirus antibodies targeting glycoprotein stem and glycan cap.

Ilinykh PA, Santos RI, Gunn BM, Kuzmina NA, Shen X, Huang K, Gilchuk P, Flyak AI, Younan P, Alter G, Crowe JE Jr, Bukreyev A.

PLoS Pathog. 2018 Aug 23;14(8):e1007204. doi: 10.1371/journal.ppat.1007204. eCollection 2018 Aug.

17.

Antibody Repertoires to the Same Ebola Vaccine Antigen Are Differentially Affected by Vaccine Vectors.

Meyer M, Yoshida A, Ramanathan P, Saphire EO, Collins PL, Crowe JE Jr, Samal S, Bukreyev A.

Cell Rep. 2018 Aug 14;24(7):1816-1829. doi: 10.1016/j.celrep.2018.07.044.

18.

Antibody-Dependent Enhancement of Ebola Virus Infection by Human Antibodies Isolated from Survivors.

Kuzmina NA, Younan P, Gilchuk P, Santos RI, Flyak AI, Ilinykh PA, Huang K, Lubaki NM, Ramanathan P, Crowe JE Jr, Bukreyev A.

Cell Rep. 2018 Aug 14;24(7):1802-1815.e5. doi: 10.1016/j.celrep.2018.07.035.

19.

Pan-Filovirus Serum Neutralizing Antibodies in a Subset of Congolese Ebolavirus Infection Survivors.

Bramble MS, Hoff N, Gilchuk P, Mukadi P, Lu K, Doshi RH, Steffen I, Nicholson BP, Lipson A, Vashist N, Sinai C, Spencer D, Olinger G, Wemakoy EO, Illunga BK, Pettitt J, Logue J, Marchand J, Varughese J, Bennett RS, Jahrling P, Cavet G, Serafini T, Ollmann Saphire E, Vilain E, Muyembe-Tamfum JJ, Hensely LE, Simmons G, Crowe JE Jr, Rimoin AW.

J Infect Dis. 2018 Nov 5;218(12):1929-1936. doi: 10.1093/infdis/jiy453.

20.

Systematic Analysis of Monoclonal Antibodies against Ebola Virus GP Defines Features that Contribute to Protection.

Saphire EO, Schendel SL, Fusco ML, Gangavarapu K, Gunn BM, Wec AZ, Halfmann PJ, Brannan JM, Herbert AS, Qiu X, Wagh K, He S, Giorgi EE, Theiler J, Pommert KBJ, Krause TB, Turner HL, Murin CD, Pallesen J, Davidson E, Ahmed R, Aman MJ, Bukreyev A, Burton DR, Crowe JE Jr, Davis CW, Georgiou G, Krammer F, Kyratsous CA, Lai JR, Nykiforuk C, Pauly MH, Rijal P, Takada A, Townsend AR, Volchkov V, Walker LM, Wang CI, Zeitlin L, Doranz BJ, Ward AB, Korber B, Kobinger GP, Andersen KG, Kawaoka Y, Alter G, Chandran K, Dye JM; Viral Hemorrhagic Fever Immunotherapeutic Consortium.

Cell. 2018 Aug 9;174(4):938-952.e13. doi: 10.1016/j.cell.2018.07.033.

Supplemental Content

Loading ...
Support Center